Neurobiology of Addition Medicine Flashcards

You may prefer our related Brainscape-certified flashcards:
1
Q

mesolimbic DA pathway

A

projection from ventral segmental area (VTA, area A10) –> nucleus accumbens

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

corticolimbic pathway

A

projections from VTA –> prefrontal cortex

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

nigrostriatal pathway

A

projections from SN (area A9) –> dorsal striatum

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

How GABAergic projections to the mesolimbic DA system modulate DA release in addiction

A

GABA projections from NA go to ventral palladium and inhibit GABA cells, creates “inhibition of inhibition = excitation” effect

those VP GABAs usually inhibit DA in VTA,
so if inhibiting those ultimately releasing more DA –> excitation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

How glutamatergic projections to the mesolimbic DA system modulate DA release in addiction

A

DA release from VTA to prefrontal cortex –> glutamate release from prefrontal cortex to VTA –> release more DA, EXCITATION

or

glutamate release from prefrontal cortex to NA –> GABA release from NA to VTA –> INHIBITION of DA release

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

nicotine

A

acts at ligand-gated ion channels that comprise VTA nicotinic ACh receptors

gate Na+ and allow selective permeation of Ca++

dominantly PRESYNAPTIC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

cocaine

A

DA reuptake blocker from synapse by blockade of DAT

*cocaine reward is intact in DAT KO mice, poss due to reuptake blockade of DA at NEPI/5HT transporters

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

amphetamines

A

targets monoamine storage

competitive ligand to DAT and VMAT2 transporters (amphetamine builds up in vesicle, displaces DA to cytosol and extracellular space)

DAT starts to work in reverse and pump DA out of the cell and into synaptic cleft

  • amphetamine also partial blocks normal DAT reuptake
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

opioids

A
  • Activate metabotropic μ-opioid receptors on VTA cells. (G protein-linked receptor)
  • Normal endogenous ligands: Endomorphin, Enkephalin, Dynorphin.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

cannabinoids

A
  • Activate metabotropic G protein-linked CB1 receptors on VTA cells primarily in CNS
  • Also activate peripheral CB2 receptors
  • Endogenous ligand: Anandamide
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Barbiturates/Benzodiazepines

A

CNS depressants, sedatives, anxiolytics

  • work at allosteric sites on GABA-gated chloride ion channels (Increase length of channel opening or frequency of firing)
  • Increases inhibition of feedback from NA to VTA
  • also blocks AMPA glutamate receptors –> CNS depression and relaxation, not euphoria (does not inc DA release).
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

EtOH effects on GABA receptors

A
  • Positive allosteric modulator of GABA-A –> inhibition of GABAergic VTA neurons –> disinhibiting dopaminergic neurons in the VTA (euphoria)
  • XS activity causes downregulation of GABA-A receptors
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

EtOH effects on NMDA receptors

A
  • Negative modulator of NMDA receptors –> increased neuronal excitability (EtOH w/d symptoms)
  • XS activity causes upregulation of NMDA receptors
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

EtOH w/d

A

aroused and hyper-aggressive

  • downregulated GABA-A receptors
  • upregulated of NMDA receptors
  • increased neuronal excitability during acute w/d
  • decreased DA release
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Phencyclidine (PCP)

A

hallucinogen-dissociative anesthetic

blocks NMDA glutamate-gated ion channels and nAChr

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Lysergic acid diethyl amide (LSD)

A

hallucinogen-dissociative anesthetic

partial agonist of 5-HT2A receptor in CNS, binds almost all monoaminergic receptors